Virinchi Ltd. (VIRINCHI) AI Stock Analysis

• Market Cap: ₹1.73B
• Dividend Yield: N/A
• Average Volume (3M): 49.69K
• Price to Earnings (P/E): 41.4
• Beta (1Y): 1.16
• Revenue Growth: -1.40%
• EPS Growth: -238.47%
• Country: IN
• Employees: 1,033
• Sector: Healthcare
• Sector Strength: 45
• Industry: Software - Application
• EPS (TTM): 0.16
• Shares Outstanding: 102,646,900
• 10 Day Avg. Volume: 10,427
• 30 Day Avg. Volume: 49,685
• PEG Ratio: -3.21
• Price to Book (P/B): 0.47
• Price to Sales (P/S): 0.74
• P/FCF Ratio: -8.73
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 6.4
• Revenue Forecast (FY): ₹3.51B

• Rating: 49 Neutral
• Price Target: ₹17.00 ▼(-28.60% Downside)
• Action: Reiterated Date: 11/25/25
• Date: Action: Reiterated 11/25/25

Virinchi Ltd.'s stock score is primarily impacted by its weak financial performance and poor valuation metrics. The technical analysis indicates bearish momentum, further contributing to the low score. The absence of earnings call data and corporate events means these factors did not influence the score.

Positive Factors

Strong equity base / conservative leverage

A strong equity base and reasonable debt-to-equity provide durable financial cushioning and financing optionality. This supports capital allocation for product development or client investments, reduces insolvency risk during cycles, and helps preserve strategic flexibility over months.

Stable gross profit margin

Stable gross margins indicate sustained control over direct delivery costs and pricing power in services. That structural margin stability provides a foundation to absorb SG&A pressures or invest in efficiency initiatives, preserving long-term operating leverage potential.

Positive operating cash flow

Positive operating cash flow demonstrates the core business converts revenue into cash, supporting near-term working capital and operations without immediate external funding. Even if cash generation has weakened, ongoing positive OCF is a durable source to manage obligations and fund incremental investments.

Negative Factors

Falling return on equity

A significantly lower ROE signals the business is delivering reduced returns on shareholder capital, reflecting persistent margin or efficiency deterioration. Over months this erodes shareholder value creation, tightens capital access, and pressures management to restore operational performance.

Negative free cash flow / conversion inefficiency

Negative free cash flow and weak conversion from earnings to cash are structural concerns: they limit reinvestment, force reliance on external financing, and constrain strategic initiatives. Persistent FCF deficits reduce runway for growth projects and raise refinancing risk over months.

Revenue decline and collapsing EPS

A contracting top line combined with a massive EPS decline points to weakening demand, pricing pressure, or client losses. Over a multi-month horizon, falling revenues and earnings undermine scale economics, margin recovery prospects, and the ability to invest in product or sales capacity.

Virinchi Ltd. Business Overview & Revenue Model

Company Description

Virinchi Limited provides information technology (IT) products and services worldwide. The company operates through Development of Computer Software and Services, IT Enabled Services, and Healthcare Services segments. It offers QFund, an IT solution for short-term mortgage and lending industry; vCard, an UPI-based credit card; V23, a healthcare practice management and patient engagement solution; IT services, such as lifecycle management, ECM services, IT infrastructure management, and IT staff augmentation and consulting services; software development; and data science and analysis services. The company also provides media and entertainment, catering, educational, infrastructure, pharmacy supply chain, fintech, healthcare, financial consulting, and short-term lending services. In addition, it owns and manages Virinchi multi-specialty hospitals and Bristlecone Hospitals. The company was formerly known as Virinchi Technologies Limited and changed its name to Virinchi Limited in January 2016. Virinchi Limited was incorporated in 1990 and is headquartered in Hyderabad, India.

How the Company Makes Money

null

Virinchi Ltd. Financial Statement Overview

Summary

Virinchi Ltd. faces challenges in profitability and cash flow, with stable revenue but declining net profit and cash flow margins. The balance sheet remains strong, but operational efficiency is under pressure.

Income Statement

Virinchi Ltd. has shown a challenging revenue performance with a slight increase from 2024 to 2025. The Gross Profit Margin is stable, but Net Profit Margin has seen a sharp decline due to a significant drop in net income. The EBIT and EBITDA margins have also decreased, indicating pressure on operational efficiency.

Balance Sheet

The company maintains a strong equity base with a reasonable Debt-to-Equity Ratio. However, the Return on Equity has decreased significantly, reflecting reduced profitability. The Equity Ratio remains stable, supporting asset-backed equity financing.

Cash Flow

Cash flow from operations remains positive but has decreased from previous years. Free Cash Flow has turned negative, indicating potential issues in covering capital expenditures. The Operating Cash Flow to Net Income Ratio suggests some inefficiencies in converting earnings into cash.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	2.93B	3.01B	3.00B	3.12B	3.64B	3.54B
Gross Profit	1.70B	1.35B	1.79B	1.93B	3.36B	3.31B
EBITDA	865.78M	963.86M	1.14B	1.11B	1.04B	1.02B
Net Income	-137.78M	7.24M	137.03M	128.49M	143.05M	27.46M
Balance Sheet
Total Assets	8.31B	8.47B	8.51B	7.87B	7.03B	6.87B
Cash, Cash Equivalents and Short-Term Investments	55.95M	77.58M	200.25M	307.08M	366.00M	190.21M
Total Debt	2.95B	2.92B	3.30B	3.17B	2.76B	2.61B
Total Liabilities	3.72B	3.73B	3.97B	3.80B	3.33B	3.12B
Stockholders Equity	4.61B	4.76B	4.55B	4.08B	3.71B	3.76B
Cash Flow
Free Cash Flow	22.61M	-253.64M	26.54M	-377.22M	525.18M	-1.04B
Operating Cash Flow	65.92M	536.65M	1.16B	987.00M	846.73M	498.55M
Investing Cash Flow	-38.08M	-778.34M	-1.15B	-1.37B	-336.79M	-1.54B
Financing Cash Flow	-49.47M	119.01M	-127.06M	323.82M	-334.14M	1.15B

Virinchi Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 23.81
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:VIRINCHI, the sentiment is Negative. The current price of 23.81 is above the 20-day moving average (MA) of 19.23, above the 50-day MA of 20.44, and below the 200-day MA of 24.74, indicating a bearish trend. The MACD of -0.81 indicates Positive momentum. The RSI at 29.00 is Positive, neither overbought nor oversold. The STOCH value of 10.70 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:VIRINCHI.

Virinchi Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALPA	60 Neutral	₹1.25B	21.48	―	―	14.53%	-10.49%
BAFNAPH	58 Neutral	₹2.56B	48.53	―	―	-0.77%	2055.99%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VIRINCHI	49 Neutral	₹1.73B	41.39	―	―	-1.40%	-238.47%
AAREYDRUGS	48 Neutral	₹1.90B	84.53	―	―	-17.47%	-50.07%
KREBSBIO	41 Neutral	₹1.05B	-11.90	―	―	-46.31%	-26.28%

Virinchi Ltd. Corporate Events

Virinchi Limited Posts Higher Profit and Revenue in Q3 FY2025-26 Unaudited Results

Virinchi Limited reported strong unaudited standalone financial results for the quarter and nine months ended December 31, 2025, with quarterly revenue from operations rising to Rs 4,283.70 lakh and total income reaching Rs 4,846.73 lakh. Profit before tax for the quarter climbed to Rs 1,159.14 lakh and net profit after tax to Rs 838.42 lakh, marking a significant improvement over the same period last year and reflecting enhanced operational efficiency and cost management, as seen in controlled administrative expenses and steady employee costs; for the nine-month period, total income grew to Rs 13,893.02 lakh and net profit to Rs 2,208.20 lakh, underscoring the company’s sustained earnings momentum and potentially strengthening its position and attractiveness to shareholders.

Virinchi Board Clears December Quarter Financials with Profit Uptick

Virinchi’s board approved the unaudited standalone and consolidated financial results for the quarter and nine months ended 31 December 2025, with standalone revenue rising to Rs4,283.7 lakh and quarterly profit after tax strengthening to Rs838.42 lakh, reflecting ongoing expansion in service demand. The company’s nine-month profit of Rs2,208.2 lakh and improving operating margins signal resilient execution heading into the fiscal year-end, underscoring steady positioning in its target industries despite higher personnel and administrative costs.

Virinchi Board Seeks Shareholder Nod for Promoter’s Investment in Healthcare Subsidiary

Virinchi Limited’s board has approved seeking shareholder approval via postal ballot for a preferential allotment of convertible equity warrants to promoter Viswanath Kompella in its material subsidiary, Virinchi Health Care Private Limited, for an investment of up to 49% of the subsidiary’s equity share capital. The company expects this capital infusion to strengthen the subsidiary’s balance sheet, improve liquidity, and enhance long-term shareholder value, with the move framed as part of a broader push to support ongoing businesses and reinforce the group’s financial and operational positioning, subject to statutory shareholder approvals under SEBI regulations and the Companies Act.

Virinchi Allots 7.4 Million Convertible Warrants to Promoter Group Entity

Virinchi Ltd has approved the allotment of 7.4 million convertible equity warrants at Rs 28 each, carrying a face value of Rs 10 and a premium of Rs 18, on a preferential basis to promoter group entity Vivo Bio Tech Limited. The warrants have been issued after shareholder approval at an extraordinary general meeting and in-principle approvals from both BSE and NSE, with 25% of the issue price already received and the remaining 75% payable upon conversion into fully paid equity shares; as only warrants have been issued so far, there is currently no change in Virinchi’s paid-up share capital, but the move sets up a pathway for potential future equity infusion and promoter group strengthening once the warrants are exercised.

Virinchi Allots 4 Million Convertible Equity Warrants on Preferential Basis

Virinchi Limited has approved the allotment of 4 million convertible equity warrants on a preferential basis to IT Peer Technologies LLC at an issue price of Rs 28 per warrant, comprising a face value of Rs 10 and a premium of Rs 18, following shareholder approval and in-principle clearances from both BSE and NSE. The warrants, issued after receipt of 25% of the consideration, will be convertible into an equal number of fully paid equity shares upon payment of the remaining 75%, and as the conversion has not yet occurred, there is currently no change in the company’s paid-up share capital, indicating a staged capital-raising structure that will only dilute equity once the balance funds are received.